Data show ELOXATIN-based therapy combined with Bevacizumab improves survival.
Publication: Vaccine Weekly
Publication Date: 29-DEC-04
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
2004 DEC 29 - (NewsRx.com & NewsRx.net) -- Podvin +331-53-77-4223
Patients who received ELOXATIN-based chemotherapy (FOLFOX4) plus bevacizumab (Avastin) showed a statistically significant improvement in overall survival in a large randomized clinical study sponsored by the U.S. National Cancer Institute and conducted by the Eastern Cooperative Oncology Group (ECOG).
Preliminary results announced are showing a 26% reduction in the risk of death for patients receiving FOLFOX4 plus bevacizumab (Avastin) compared to FOLFOX4 alone.
According to the U.S. National Institutes of Health, researchers...
Read the full article for free courtesy of your local library.
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
